Abraxis BioScience, Inc., formerly American Pharmaceutical Partners, Inc., incorporated in 2001, is a pharmaceutical company that develops, manufactures and markets injectable pharmaceutical products. It manufactures products in each of the three basic forms, in which injectable products are sold: liquid, powder and lyophilized, or freeze-dried. The Company has the right to sell Abraxane, a nanoparticle injectable oncology product, in North America. In January 2005, American BioScience (ABI)'s new drug application (NDA) for Abraxane was approved by United States Food and Drug Administration (FDA) and the Company launched the product on February 7, 2005. On November 27, 2005, the Company entered into a merger agreement with ABI. During the year ended December 31, 2005, the Company has 23 abbreviated new drug applications pending and over 70 product candidates under development across oncology, anti-infective and critical care product categories. The Company's wholly owned subsidiary, Pharmaceutical Partners of Canada, Inc., markets injectable pharmaceutical products in Canada. Injectable Oncology Products During the year ended December 31, 2005, Abraxis BioScience, Inc. manufactured and marketed 17 injectable oncology products in 33 dosages and formulations. In 2005, its oncology products represented 36% of the total net sales. The Company's oncology products include Carboplatin, Pamidronate, Cisplatin, Ifosfamide and Mesna. Carboplatin is indicated for the initial treatment of advanced ovarian carcinoma in combination with other chemotherapeutic agents and for the palliative treatment of recurrent ovarian carcinoma after prior chemotherapy. Pamidronate disodium is a bone-resorption inhibitor used to treat hypercalcemia associated with a malignancy, with or without bone metastates and Paget's disease. Cisplatin is a chemotherapy agent used alone or in combination with other agents to treat metastatic testicular or ovarian cancer, Hodgkin's disease, non-Hodgkin's lymphoma, brain tumors, cancer of the nervous system and head, neck, bone, cervical, lung and bladder cancer. Ifosfamide is a chemotherapy drug used to treat germ cell testicular cancer and is often given in combination with Mesna. Mesna is a cytoprotectant used to treat the side effects associated with certain chemotherapy drugs. Injectable Anti-Infective Products Abraxis BioScience, Inc. and manufactures and markets 18 injectable anti-infective products. In 2005, it represented 33% of the total net sales. Its anti-infective product line includes Cefoxitin, Vancomycin, Doxycycline, Ampicillin and Gentamicin. Cefoxitin is a second-generation cephalosporin with a range of anti-microbial activity. Cefoxitin is often used for gynecological infections, especially in peri-operative prophylaxis. Many infections caused by gram-negative bacteria resistant to some cephalosporins and penicillins respond to cefoxitin. Vancomycin is an antibiotic used to treat some types of Staph, Strep or other infections, particularly in patients who are allergic to penicillins or cephalosporins. Doxycycline is an antibiotic used to treat anthrax, Rocky Mountain Spotted Fever, typhus and mycoplasma pneumonia. Ampicillin is a penicillin-based antibiotic, which treats various types of infections of the skin, central nervous system, heart, respiratory tract, sinuses, ear and kidney. Gentamicin is an antibiotic used to treat endocarditis, septicemia and bacterial, bone, respiratory tract, soft tissue, urinary tract and other infections. Injectable Critical Care Products Abraxis BioScience, Inc. manufactures and markets more than 61 injectable critical care products. In 2005, it represented 32% of the total net sales. The Company's critical care products include Heparin and Oxytocin. Injectable heparin is a blood thinner used to prevent and treat blood clotting, especially during and after surgery. Oxytocin is used to induce labor at term and control postpartum bleeding. The Company competes with Hospira, Bedford Laboratories, Baxter Laboratories, Teva, Faulting Pharmaceuti

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for ABBI